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Epithelial-mesenchymal transition (EMT) contributes to cell invasion and metastasis 
during the progression of epithelial cancers. Though preclinical evidence suggests a role 
for histamine H4 receptor (H4R) in breast cancer growth, its function in the EMT is less 
known. In this study we proposed to investigate the effects of H4R ligands on EMT and 
mammosphere formation as a surrogate assay for cancer stem cells in breast cancer 
cells with different invasive phenotype. We also investigated the participation of Src and 
TGF-β signaling in these events. 
Breast cancer cells were treated with the H4R agonists Clobenpropit, VUF8430 and 
JNJ28610244 and the H4R antagonist JNJ7777120. Immunodetection studies showed 
cytoplasmic E-cadherin, cytoplasmic and nuclear beta-catenin, nuclear Slug and an 
increase in vimentin and α-smooth muscle actin expression. There was also an 
enhancement in cell migration and invasion assessed by transwell units. All these 
effects were prevented by JNJ7777120. Moreover, H4R agonists induced an increase in 
phospho-Src levels detected by Western blot. Results revealed the involvement of 
phospho-Src in EMT events. Upon treatment with H4R agonists there was an increase 
in phospho-ERK1/2 and TGF-β1 levels by Western blot, in Smad2/3 positive nuclei by 
indirect immunofluorescence, and in tumor spheres formation by the mammosphere 
assay. Notably, the selective TGF-β1 kinase/activin receptor-like kinase inhibitor A83-01 
blocked these effects. Moreover, cells derived from mammospheres exhibited higher 
Slug expression and enhanced migratory behavior. 
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Collectively, findings support the interaction between H4R and TGF-β receptor signaling 
in the enhancement of EMT features and mammosphere formation and point out 
intracellular TGF-β1 as a potential mediator of these events.  
 
























Breast cancer is a heterogeneous disease mainly involved in women death worldwide 
being metastasis rather than the primary tumor a relevant player in breast cancer 
mortality [1]. Epithelial-mesenchymal transition (EMT) is a physiologic program 
associated with organogenesis and tissue remodeling. However, accumulating evidence 
shows that EMT is improperly activated and contributes to cell invasion and metastasis 
during the progression of epithelial cancers. This critical program comprises a sequence 
of cellular events including morphological changes, loss of epithelial markers (E-
cadherin, desmoplakin, Muc-1, cytokeratin-18, occludins, claudins, and ZO-1) and 
acquisition of mesenchymal markers (N-cadherin, vimentin, fibronectin, vitronectin, α-
smooth muscle actin, and FSP1) [2]. Moreover, EMT induces the expression of 
transcription factors as Slug, Snail, ZEB and Twist, which in turn regulate the expression 
of other genes that may confer invasive and metastatic properties to cancer cells [3,4]. 
Histamine (HA) is a pleiotropic amine that exerts its physio-pathologic actions through 
the activation of four different receptors H1, H2, H3, H4 (H1R-H4R). These receptors 
belong to the seven membrane G protein coupled receptors (GPCR) family and diverse 
signaling pathways are described to be activated by HA or HA receptors ligands 
stimulation [5]. HA receptors are present in several neoplasms and malignant cell lines 
[6]. A great body of research supports the relevant role of HA in cancer biology through 
the modulation of cell growth and tumor microenvironment. Interestingly, the biological 
responses observed in each case are dependent on HA concentration, HA receptor 
involved, signaling pathways activated, tissue or cell type and tumor microenvironment 
as recently reviewed [6]. Moreover, high intracellular HA content and release together 
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with the expression of HA receptors modulating cell growth uphold a potential role of HA 
as an autocrine growth factor in different tumor tissues and cell lines [6]. Remarkably, 
several reports reveal that conjugation of 5,6α-epoxycholesterol with HA produces 
Dendrogenin A (DDA) which functions as a tumor suppressor metabolite in mammalian 
[7,8]. Deregulation of DDA biosynthesis in cancer might contribute to endogenous HA 
action on tumor cell growth since DDA concentration drastically decreases in tumor 
tissues when compared to healthy tissues. 
During the last decade, pharmacology research on H4R (the last HA receptor 
discovered) has become important in the context of immune and inflammatory disorders. 
H4R is expressed in cells of the immune system and in different tissues [5]. Particularly, 
H4R is present in normal and neoplastic mammary tissues and cell lines. H4R 
expression is higher in carcinomas than in benign lesions being also associated with 
invasive and aggressive tumors [9]. It was reported that H4R agonists inhibit MCF-7 and 
MDA-MB-231 breast cancer cells proliferation [10]. In vivo studies employing MDA-MB-
231 xenotransplanted tumors revealed that the H4R agonists exert an inhibitory action 
on tumor growth even though the H4R agonist JNJ28610244 produces a significant 
increase in lung metastases [11]. In agreement, we have previously reported that the 
H4R agonist VUF8430 or low doses of HA may enhance the activity of metalloproteases 
and the migratory capacity of MDA-MB-231 cells [12]. 
The transforming growth factor-β (TGF-β) is a multifunctional cytokine linked to cell 
growth and differentiation, embryogenesis, immunity, tissue remodeling, fibrosis, and 
cancer. A dual role for this cytokine has been long discussed in cancer. It is known as a 
tumor suppressor agent at the beginning of carcinogenesis meanwhile it then assists 
cancer progression and metastasis by promoting neo-angiogenesis, escape of 
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immunosurveillance and EMT [13-15]. TGF-β binds and activates cell surface receptor 
serine/threonine kinase complexes, including TGF-β receptor type II and TGF-β receptor 
type I. Consequently, Smad family members 2 and 3 are phosphorylated, form a stable 
complex with Smad family member 4, move to the nucleus, and regulate target genes 
transcription [13]. In addition, there are non-Smad pathways (MAPK, PI3K/AKT and Rho 
family GTPases) induced by TGF-β which supplement the canonical via (Smad) driving 
the cellular responses [16]. 
Breast cancer stem cells (BCSCs), a small set of cells with properties of stem-like cells, 
are involved in the heterogeneous population present in the tumor bulk of breast cancer. 
BCSCs exhibit the phenotype CD44+/CD24−/low, form mammospheres in a serum-free 
medium and non-adherent condition and initiate tumors in immunocompromised mice 
[17]. Accumulating evidence shows that EMT is involved in BCSCs generation [18,19].  
In this study, we proposed to improve the knowledge about the effects of histamine H4R 
ligands on EMT induction and mammosphere formation in breast cancer cells and 
investigate the participation of Src and TGF-β signaling in these events as well. 
 
2. Materials and Methods 
 
2.1 Cell culture 
MCF-7 and MDA-MB-231 mammary carcinoma cells were purchased from American 
Type Culture Collection (ATCC, USA). Cells were subcultured according to the ATCC 
protocol within 2 months of resuscitation and used between passages 5 and 20. Cell 
cultures were mycoplasma tested monthly using DAPI as a direct DNA stain. 
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MCF-7 and MDA-MB-231 cell lines exhibit distinct invasive properties. MCF-7 cells 
represent the luminal breast cancers; they are non-invasive and show a cobblestone 
morphology and low migratory capacity. MDA-MB-231 cells represent the triple negative 
breast cancer (TNBC). They are highly invasive and show a more elongated 
morphology. Both cell lines express the four histamine (H1-H4) receptor subtypes [9].  
Cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum 
(FBS, Gibco, CA, USA), 0.3 g/L L-glutamine and 40 mg/L gentamicin at 37ºC in a 
humidified atmosphere with 5% CO2. Twenty-four hours after plating cells were treated 
with the following selective H4R ligands: Clobenpropit (CLOB; H3R antagonist/H4R 
agonist; 3-(1H-imidazol-5-yl)propyl N'-[(4-
chlorophenyl)methyl]carbamimidothioate;dihydrobromide; Tocris Bioscience, UK), VUF 
8430 (VUF; H4R agonist; 2-(diaminomethylideneamino)ethyl 
carbamimidothioate;dihydrobromide; Sigma-Aldrich, St Louis, MO, USA), JNJ28610244 
(JNJ28, H4R agonist; (Z)-(5-methyl-1H-indol-2-yl)-(1-methyl-piperidin-4-yl)-methanone 
oxime, Janssen Research & Development, San Diego, USA) and JNJ7777120 (J77; 
H4R antagonist; (5-chloro-1H-indol-2-yl)-(4-methylpiperazin-1-yl)methanone; Sigma-
Aldrich, St Louis, MO, USA). Since the H4R agonists exert an inhibitory effect in MCF-7 
and MDA-MB-231 cell proliferation [10], we performed all our experiments using both 
breast tumor cells after 5 days of treatment to assure that we were working with the 
surviving cells. The H4R antagonist J77, the selective inhibitor of Src-family tyrosine 
kinases PP2 (4-Amino-3-(4-chlorophenyl)-1-(t-butyl)-1H-pyrazolo[3,4-d] pyrimidine, 
Sigma-Aldrich, St Louis, MO, USA) and the selective TGFβ kinase/activin receptor-like 
kinase inhibitor A83-01 (A83, 3-(6-methylpyridin-2-yl)-N-phenyl-4-quinolin-4-ylpyrazole-
1-carbothioamide, Santa Cruz Biotechnology, TX, USA) were added to cell cultures 30 
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min before H4R agonists for combined treatments. We selected the concentrations of 
H4R ligands and inhibitors for this study in agreement with our previous reports and 
other researchers' work [10-12,20]. These concentrations are mentioned in legends.  
 
2.2 Immunoblotting 
Immunoblots were carried out as previously described [20]. Briefly, 30-50 µg of protein 
were separated on a 12% SDS-PAGE gel. Blue Plus® IV Protein Marker (10-180 kDa), 
DM131-01, from TransGen Biotech Co, Beijing, China was used. Gels were blotted onto 
a polyvinylidenedifluoride membrane, blocked and finally probed with anti E-cadherin 
(1:400, Santa Cruz Biotechnology, TX, USA; sc 8426; lot #H0417), anti vimentin (1:500, 
Invitrogen, CA, USA, 18-0052; lot 1484697A), anti α-SMA (1:500, Abcam, Cambridge, 
UK; ab5694), anti N-cadherin (1/500, Invitrogen, NY, USA; #33-3900), anti β-catenin 
(1:400, Santa Cruz Biotechnology, sc 7963; lot B2217), anti Slug (1:200, Santa Cruz 
Biotechnology, TX, USA ;sc 166476; lot #G1317), anti phospho-Src (1:250, Cell 
Signaling, MA, USA; #2101), anti Src (1:250, Cell Signaling, MA, USA; #2108), anti 
TGF-β1 (1:250, Abcam, Cambridge UK, ab27969; lot #GR3193029-1), anti phospho-
ERK 1/2 (1:500, Santa Cruz Biotechnology Inc., TX, USA; sc-7383), anti ERK1/2 (1:500, 
Santa Cruz Biotechnology Inc., TX, USA; sc- 514302),anti β-actin (1:2000, Sigma-
Aldrich, St Louis, MO, USA ; A5441; lot #014M4759) or α-tubulin (1:2000, Sigma-
Aldrich, St Louis, MO, USA; T8203; lot #059M4863V) antibodies overnight and with anti-
mouse IgG (whole molecule) horseradish peroxidase-conjugated (1:3000, Sigma-
Aldrich, St Louis, MO, USA; A9044; lot #052M4826) antibody or anti-rabbit IgG (H+L)-
HRP conjugate (1:2000, Bio-Rad, CA, USA; 1706515) for 1 h at room temperature. The 
immunoreactive bands were detected by enhanced chemiluminescence (ECL, 
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Amersham Biosciences, Argentina) and analyzed by densitometry using the software 
ImageJ 1.42q (NIH, USA).  
 
2.3 Immunofluorescence studies  
Cells grown on cover glasses were fixed, permeabilized, blocked in PBS with 1% bovine 
serum albumin (BSA) and incubated overnight at 4ºC with anti E-cadherin (1:100, Santa 
Cruz Biotechnology, TX, USA; sc 8426; lot #H0417), anti β-catenin (1:100, Santa Cruz 
Biotechnology, TX, USA; sc 7963; lot #B2217), anti Slug (1:100, Santa Cruz 
Biotechnology, TX, USA; sc 166476; lot #G1317), anti Slug (1:100, Invitrogen, 
Thermofisher Scientific, MA, USA; PA1-86737), anti phospho-Smad 2,3 (1:100, Cell 
Signaling, MA, USA; #8828) or anti CD44 HCAM (1:100, Santa Cruz Biotechnology, TX, 
USA; sc 7297, lot #H0416) antibodies and for 1 h at room temperature with Alexa Fluor 
488 dye conjugated anti-mouse IgG (H+L) (1:2000, Thermofisher Scientific, MA, USA; 
A-11017; lot #1812170) or Alexa Fluor 546 dye conjugated anti-mouse IgG (H+L) 
(1:2000, Thermofisher Scientific, MA, USA; A-11003) or anti rabbit IgG (whole 
molecule)-FITC (1:1000, Sigma-Aldrich, St Louis, MO, USA; F9887, lot 079K 4804) 
antibody plus DAPI (0.1 µg/ml) to stain nuclei. Immunoreactivity was visualized by an 
immunofluorescence microscope (Olympus Fluo View FV1000). Immunofluorescence 
studies were also performed using mammospheres.   
 
2.4 Migration and invasion assays 
Migration studies were performed as previously described [20]. Briefly, using a 24-well 
transwell unit with polyethylene terephthalate membranes showing a pore size of 8.0 µm 
(BD Falcon, Basel, Switzerland). MCF-7 (3.104) or MDA-MB-231 (5.103) cells in serum-
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free RPMI were loaded into the upper compartment. The lower chamber contained 
treatments in 10% FBS/RPMI medium. After 20 h (MDA-MB-231) or 40 h (MCF-7) at 
37ºC non-migrated cells on the upper surface of membranes were gently scrubbed with 
a cotton swab. Migrated cells were fixed in 4% formaldehyde/PBS and stained with 
0.5% crystal violet. Total migrated cells were counted with an Olympus Bx50y 
microscope and photos were taken with an Olympus DP73 camera. Results were 
expressed as the number of migrated cells compared to control. For invasion assays, 
transwell units were previously coated with Matrigel® (BD Biosciences, MA, USA)/RPMI 
(1:2) and MCF-7 (1.105) or MDA-MB-231 (1.104) cells were loaded in the upper 
chamber. Cells that invaded through Matrigel were fixed, stained and counted as 
previously described for migration studies. 
 
2.5 Mammosphere formation assay 
Mammary tumor cells were seeded and treated with H4R ligands during 5 days and then 
harvested. Next MCF-7 (104) and MDA-MB-231 cells (103) were plated into each well of 
the ultralow attachment 12-well plate in RPMI 1640 serum-free medium, supplemented 
with B27 (1:50, Invitrogen, CA, USA), 20 ng/ml basic fibroblast growth factor (Sigma-
Aldrich, St Louis, MO, USA), 20 ng/ml human epidermal growth factor (Sigma-Aldrich, St 
Louis, MO, USA), 4 µg/ml heparin, and 15 µg/ml gentamicin. After 7-9 days the number 
of mammospheres/well were determined under a Carl Zeiss inverted microscope and 
photographs were acquired with Ampscope capture software.  
 
2.6 Statistical analysis 
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One-way ANOVA and Bonferroni post-test were used to analyze data employing the 
GraphPad Prism Version 7.0 software (GraphPad Software Inc, Philadelphia, USA). For 
data with two sets that were normally distributed, an unpaired one-tailed t-test was 
conducted to determine significance. In all cases, P values less than 0.05 were 




3.1 Effects of H4R ligands on EMT molecular markers in breast cancer cells 
To understand the role of H4R ligands on the EMT induction in MCF-7 and MDA-MB-
231 breast cancer cells we employed three H4R agonists (CLOB, VUF or JNJ28) and 
the H4R selective antagonist J77 to evaluate the subcellular localization of E-cadherin, 
β-catenin, vimentin and Slug by indirect immunofluorescence (IFI). We also evaluated 
the expression of the mesenchymal markers vimentin, N-cadherin and α-smooth muscle 
actin (α-SMA) by Western blot.  
In MCF-7 cells treated with VUF or JNJ28, there was no change in the expression of the 
epithelial marker E-cadherin and in β-catenin expression by Western blot (Figure 1A). 
Moreover, we could not detect the mesenchymal markers vimentin, N-cadherin and α-
SMA in control and treated MCF-7 cells (Figure 1A). IFI studies revealed that E-cadherin 
left the cell membrane to be mainly localized in cytoplasm. In addition, nuclear beta-
catenin and Slug and a weak cytoplasmic stain for vimentin were detected by IFI upon 
VUF treatment (Figure 1B). There was also a significant increase in the number of Slug 
positive nuclei when cells received VUF (Figure 1C). In MDA-MB-231 cells, E-cadherin 
was not present as previously reported [20,21]. Notably, the H4 agonist VUF augmented 
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vimentin and α-SMA expression in a significant way while N-cadherin could not be 
detected in treated and untreated cells (Figure 1D). We also observed a change in the 
subcellular localization of β-catenin protein by IFI. We observed nuclear β-catenin and 
Slug nuclear localization in VUF-treated MDA-MB-231 cells (Figure 1E). Data revealed a 
significant increase in the number of Slug positive nuclei (Figure 1F). Remarkably, the 
H4R antagonist J77 blocked all the EMT events induced by H4R agonists in both cell 
lines (Figure 1). 
 
3.2 H4R ligands modify the migratory and invasive properties of breast cancer 
cells 
EMT is characterized by the activation of a series of events that lead to various degrees 
of epithelial plasticity and to the activation of migratory programs [3,22].  
To explore cell invasion and migration we performed invasion and migration assays 
employing migration chambers with or without Matrigel, respectively. There was a 
significant increase in the number of MCF-7 migrated cells upon CLOB or VUF 
treatment compared to non-treated cells (Figure 2A). However, this increase was not 
observed when cells received the H4R antagonist J77 previously. Figure 2B shows 
representative photos. Invasion assays also revealed that the H4R agonists VUF and 
JNJ28 significantly enhanced the invasive capability of MCF-7 cells (Figure 2C). Similar 
results were observed in MDA-MB-231 cells (Figure 2D-2F). 
The expression of CD44 in tumor cells is associated to a more aggressive and invasive 
behavior. It is known that EMT promotes CD44 expression being Slug positively 
correlated with this expression [23]. In order to explore this association, we performed 
IFI studies to detect CD44 and the EMT transcription factor Slug simultaneously in both 
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cell lines treated with the H4R agonist. Findings showed that MCF-7 cells expressed this 
positive correlation upon VUF treatment. In addition, there was a significant increase in 
MDA-MB-231 cells expressing Slug. However, we could not verify the correlation 
between Slug and CD44 due these cells were almost 100% positive for CD44 
independently of VUF treatment. This result is consistent with the more invasive traits 
that MDA-MB-231 cells exhibit. Representative photos are shown in Figure 2G while 
numerical data are seen in Table 1. 
 
3.3 Src phosphorylation mediates EMT changes and cell migration induced by 
H4R agonists 
Src is a non-receptor tyrosine kinase protein implicated in cell adhesion and migration 
through the interaction with different signaling proteins. We have previously reported 
that high doses of histamine may prevent radiation-induced mesenchymal changes and 
cell migration in breast cancer cells through Src inhibition [20]. To investigate whether 
this kinase was involved in H4R agonist-induced signaling in MCF-7 and MDA-MB-231 
cells we evaluated Src phosphorylation by Western blot. Noticeably, H4R stimulation 
with JNJ28 led to a significant increase in phospho-Src levels while the H4R antagonist 
J77 prevented this increase in both cell lines. The selective Src inhibitor PP2 also 
hindered the effect of H4R agonists on Src phosphorylation (Figure 3A). 
We then examined the participation of phospho-Src in some molecular and functional 
EMT related events, like Slug subcellular localization and cell migration, in MCF-7 and 
MDA-MB-231 cells. After five days we observed that PP2 could block the increase in 
Slug positive nuclei and reduce the number of migrated cells upon VUF or JNJ28 
treatment in both cell lines (Figure 3B, 3C). Our findings support the relevance of Src 
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activation/phosphorylation in the mesenchymal changes and in cell migration induced by 
H4R agonists.  
 
3.4 Participation of TGF-β signaling in EMT changes induced by H4R agonists 
In the last decade, GPCR transactivation of Protein Serine/Threonine Kinase receptors 
like the Transforming Growth Factor β Type I receptor (TβRI) has been described [24]. 
To explore this point, we checked phospho-Smad2/3 and phospho-ERK1/2 as 
representative molecules of the Smad and non-Smad activated TβRI signaling in MCF-7 
and MDA-MB-231 cells respectively. Results are shown in Figure 4. The H4R agonist 
VUF or JNJ28 significantly increased the number of phospho-Smad2/3 positive nuclei in 
both cells lines. Notably, this effect was blocked when tumor cells were previously 
treated with the selective inhibitor of TβRI ALK5 kinase, type I activin A83-01 (A83) 
(Figure 4A). In addition, the H4R agonists improved ERK1/2 phosphorylation while A83 
blocked this effect (Figure 4B). Our findings suggest a possible interaction between H4R 
and TβRI signaling pathways. 
Since TGF-β is a key inducer of EMT in a variety of tumor cell lines [25,26], we 
investigated intracellular and extracellular TGF-β1 levels at the time that we could 
observe mesenchymal changes induced by H4R agonists in MCF-7 and MDA-MB-231 
cells. Results indicated a significant increase in TGF-β1 intracellular levels by Western 
blot in both cell lines. Interestingly, A83 pre-treatment significantly blocked this increase 
(Figure 5A). Moreover, there was a significant enhancement in TGF-β1 content in 
conditioned media from MCF-7 and MDA-MB-231 cell cultures treated with H4R 
agonists (Figure 5B). To clarify whether TGF-β1 levels might influence the biological 
responses related to EMT we performed IFI and cell migration studies adding A83 
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before VUF or JNJ28 treatment. IFI studies revealed that A83 could prevent the Slug 
nuclear localization and the rise in Slug positive nuclei induced by H4R agonists in MCF-
7 and MDA-MB-231 cells as well (Figure 5C). We also studied the migratory behavior of 
these tumor cells after five days of treatment. The significant increase in the number of 
MCF-7 and MDA-MB-231 migrated cells upon VUF or JNJ28 treatment was reduced 
when cells were pretreated with A83 (Figure 5D). Taken together these findings suggest 
that the intracellular TGF-β1 might be an important player in the EMT events and 
migration induced by H4R agonists in breast cancer cells. 
   
3.5 Effect of H4R ligands on mammosphere formation 
BCSCs like normal mammary stem cells exhibit the ability to form mammospheres in 
serum-free medium and non-attachment conditions [17]. In order to evaluate the effect 
of H4R ligands on mammosphere generation we performed mammosphere cultures. 
Results indicated a significant increase in the number of mammospheres in MCF-7 and 
MDA-MB-231 cells treated with the H4 agonists VUF or JNJ28 while the H4R antagonist 
J77 blocked the effect (Figure 6A). Interestingly, we could observe a substantial 
reduction in tumor spheres generation when we added A83 alone or in combination with 
the H4R agonist in cell cultures. We propose the participation of the endogenous TGF-
β1 in mammosphere formation since the experimental condition for this assay requires 
cells to be cultured in serum-free medium. Moreover, intracellular TGF-β1 might 
participate in EMT events and tumor sphere formation via an autocrine loop since TGF-
β1 levels induced by H4R agonists were reduced by A83 as shown in Figure 5A. 
Evidence supports that epithelial cells may acquire stem cell traits when they undergo 
EMT [18,27]. In order to explore a potential link between the gain of mammosphere-
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forming ability and EMT we performed IFI studies to detect Slug in intact 
mammospheres and migration studies with cells derived from mammospheres. MCF-7 
cells treated with H4R agonists formed tumor spheres exhibiting Slug green fluorescent 
stain in almost all cells while cells derived from mammospheres exhibited higher 
migratory properties. Meanwhile non-treated cells generated tumor spheres showing 
cells with very low green fluorescent stain for Slug and poor migratory properties (Figure 
6B, 6C). Even though it was impossible to keep MDA-MB-231 cells in intact spheres like 
MCF-7 for IFI studies (probably due to E-cadherin absence in the cell membrane), we 
could observe that almost all cells derived from spheres were positive for Slug. 
Moreover, their migratory properties were also significantly increased (Figure 6B, 6C). 
Collectively, data support the relevance of endogenous TGF-β1 in tumor sphere 





The highly conserved cellular program called EMT is activated during tumor 
progression, metastasis, drug resistance and tumor recurrence [28]. EMT endows 
epithelial cells to acquire mesenchymal characteristics to migrate, invade and spread 
providing changes in the adhesion, motility and ability of tumor cells to degrade the 
extracellular matrix, as well as resistance to apoptosis during tumor progression and 
metastasis [2]. Signaling pathways activated by different growth factors and cytokines 
among other factors are master regulators of EMT and converge on the induction of 
transcription factors as Snail, Slug, Zeb, Twist. These EMT-transcription factors 
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downregulate the expression of epithelial markers like E-cadherin while upregulate the 
expression of mesenchymal markers in order to endow cells with changes in the 
structural proteins of the cytosketelon and cell membrane to migrate and invade [3].  
We have previously reported that HA may dose-dependently modulate gelatinolytic 
activities and cell migration in pancreatic and mammary tumor cells disclosing an 
inhibitory action over 10 µM or a stimulatory effect with doses lower than 1µM [12,29]. 
Interestingly, the H4R agonist VUF 8430 reproduced the stimulatory action in the triple 
negative breast cancer (TNBC) cell line MDA-MB-231 [12].  
In the present work, we proposed to further investigate the effects of the H4R ligands on 
EMT and mammosphere formation in MCF-7 and MDA-MB-231, breast cancer cells with 
different invasive phenotypes, and also evaluate the potential participation of Src and 
TβRI signaling in these events.  
Several reports show that HA and HA receptor ligands may regulate cell-cell adhesion 
and cadherin expression in different normal and neoplastic cells tightly dependent on the 
cell/tissue and the HA receptor subtype involved [30-32]. Our results showed 
cytoplasmic E-cadherin and cytoplasmic/nuclear β-catenin in breast cancer cells treated 
with H4R agonists. The loss of the epithelial marker E-cadherin from the cell membrane 
and changes in the subcellular localization, from membrane to cytoplasm, lead to the 
disruption of intercellular contacts so that epithelial cells separate and are able to 
migrate. The dissociation of the E-cadherin /β-catenin complex is defined as the cause-
effect relationship of the EMT process since β-catenin is a linking protein between E-
cadherin and the cytoskeleton catenins [2,33,34]. In addition, accumulating evidence 
shows that cytoplasmic β-catenin may translocate into the nucleus and act as a 
transcription factor regulating the expression of EMT related genes like SLUG, SNAIL, 
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ZEB1, TWIST and cell adhesion molecules genes as CD44 [3,35].  Our findings 
revealed that H4R agonists led to cytoplasmic and nuclear β-catenin together with a 
significant rise in the number of Slug positive nuclei and migrated cells in both cell lines. 
However, we could only observe a significant increase in CD44 positive cells in MCF-7 
but not in MDA-MB-231, probably due to their different invasive phenotype. In 
agreement with our results, Uchino and coworkers demonstrated that the non-invasive 
cells MCF-7 become aggressive and acquire an invasive phenotype showing nuclear β-
catenin and CD44 upregulation when they were subjected to a sequential invasion 
process [36]. 
Vimentin, alpha-smooth muscle actin (α-SMA) and N-cadherin are described as 
acquired mesenchymal markers in cells ongoing EMT [37]. Vimentin is a cytoskeletal 
protein present in mesenchymal normal cells that participates in attachment, migration, 
and cell signaling. Its upregulation or its de novo synthesis is a mechanism associated 
with EMT in tumors [38,39]. In the present study H4R agonists increased the expression 
of vimentin in MDA-MB-231 cells while promoted its appearance in MCF-7 cells. α-SMA, 
a cytoskeletal marker is usually present in smooth muscle actin, myofibroblasts and 
blood vessels. However, a high expression of α-SMA has been reported in tumor cells 
linked to invasive and metastatic behavior and poor prognosis [40]. Our results show a 
significant enhancement of α-SMA expression induced by the H4R agonist VUF in MDA-
MB-231 cells but this protein could not be detected in treated and untreated MCF-7 
cells. In agreement with our data, evidence supports the presence of α-SMA in the more 
invasive and aggressive breast cancer, the basal-like breast cancer phenotype [41]. N-
Cadherin is a mediator in cell-cell adhesion in epithelial tissues with different roles 
during normal development and tumor progression. The replacement of E-cadherin by 
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N-cadherin leads to weaker cell-cell adhesions between adjacent cells. Though this 
switch is a typical EMT event related to cancer [42], we could not detect N-cadherin 
expression, either in control MCF-7 and MDA-MB-231 cells as reported [21,43] or in 
cells treated with the H4R agonists. In summary, we observed the loss of E-cadherin in 
cell membrane without changes in its expression level, an increase in Slug and β-
catenin nuclear localization and a weak cytoplasmic vimentin expression in MCF-7 cells 
treated with H4R agonists. Taken together these findings showed that treated MCF-7 
cells exhibit some mesenchymal attributes usually acquired by epithelial cells 
undergoing EMT. Emerging evidence shows that EMT program is not a binary switch to 
move cells from a full epithelial to a full mesenchymal state [44,45]. Cells undergoing 
EMT may retain certain epithelial markers while exhibit some mesenchymal markers; 
this is described as partial EMT. At present, it is known that most tumor cells do not go 
through a full EMT. As regards MDA-MB-231, control cells show vimentin and α-SMA 
expression and important Slug and β-catenin nuclear localization which were 
significantly increased by the H4R agonist treatment, indicating an enhancement of 
mesenchymal features. It is well known that the structural changes acquired by epithelial 
cells through EMT contribute to motility and invasiveness [44]. Notably consistent, our 
data reveal that H4R agonists also increased cell migration and invasion in both cancer 
cell lines. Unlike our results, other authors have reported a disruption of EMT by H4R 
agonists in cholangiocarcinoma cells [46] and in human non-small cell lung cancer 
(NSCLC) [47].  
Histamine H4R is a Gi/G0-coupled GPCR that signals increasing intracellular Ca2+ and 
activates kinases such as ERK, PI3K and P38 [5]. Additionally, direct and indirect 
mechanisms of Src family kinases activation by GPCR have been described [48]. We 
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have previously reported that histamine in high concentration may prevent the radio-
induced EMT and migration through the inhibition of Src phosphorylation in MCF-7 and 
MDA-MB-231 cells [20]. In this study, we confirm the participation of activated Src in 
EMT events and migration of both cell lines treated with H4R agonists.   
Diverse signaling pathways are involved in EMT induction [49]. Among them, TGF-β 
canonical and non-canonical pathways play an important role in normal and neoplastic 
human mammary epithelial cells [50]. We hypothesized that GPCR transactivation of 
TGF-beta receptor might contribute to H4R agonist-induced EMT. In this regard, we 
found that H4R agonists significantly increased the number of P-Smad2/3 positive nuclei 
and also enhanced ERK1/2 phosphorylation in MCF-7 and MDA-MB-231 cells. Besides, 
the selective TGF-β kinase/activin receptor-like kinase inhibitor A83 prevents these 
increases and the mesenchymal changes induced by H4R agonists in both cell lines. 
We propose a potential interaction between H4R and TGF-β signaling. In line with our 
results, it has been reported the crosstalk between G-coupled receptor proteinase 
activated receptor 2 (PAR2) and TGF-β signaling, via Smad2/3 and P38 MAPK, to 
enhance migration/invasion and metastasis in advanced pancreatic adenocarcinoma 
[51]. Based on our findings, Src activation/phosphorylation might be upstream or 
downstream TGF-β signaling; we need to investigate it. 
TGF-β1 is considered a key player for EMT and for the maintenance of the 
mesenchymal and stem cell state in the breast [18,50,52]. In a previous study, we 
demonstrated that conditioned media from fibroblasts treated with histamine in high 
concentration (20 µM) decrease TGF-β1 levels in MDA-MB-231 cells and block EMT 
events supporting the TGF-β1 contribution to EMT-related changes induction via a 
paracrine or autocrine loop [21]. In this study, we found that H4R stimulation led to a 
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significant increase in intra and extra cellular TGF-β1 levels at the time we could 
observe the mesenchymal changes in MCF-7 and MDA-MB-231 cells. Our results are 
opposite to those reported by Cai et al. who described that H4R stimulation in NSCLC 
impedes EMT progress by inhibiting the TGF-β1 signaling pathway and by reducing 
levels of several important EMT transcription factors such as ZEB1, Snail and Slug [47]. 
However, Cai and coworkers have recently demonstrated that genetic variations in the 
H4R gene may affect H4R function and so attenuate the anti-EMT effect of this receptor 
in NSCLC as well as the outcome of these patients [53]. Particularly in breast cancer, 
data from a case-control study performed in Chinese Han populations support the idea 
that the genetic variations of histamine H4R may also affect the EMT process and 
metastasis when considering the association between H4R polymorphisms and 
clinicopathological characteristics of breast cancer [54]. Genetic dysfunctions of H4R 
should be considered and investigated in MDA-MB-231 and MCF-7 cells.  
BCSCs are present in different breast tumors and cell lines and their involvement in 
radio- and chemo-resistance, tumor recurrence and cell spreading has been extensively 
commented [18,55]. BCSCs have been identified by the expression of cell-surface 
markers like CD44+/CD24-/low and ALDH+. Cells with these phenotypes are able of 
generating a tumor in serial dilution tumorigenesis assays in immunodeficient mice, the 
golden standard for evaluating CSC properties. In addition, BCSCs cells form 
mammospheres in non-adherent culture. Given the ability of mammosphere cells to 
induce tumors in immunocompromised mice [56,57], mammosphere culture, as a 
surrogate assay, has been used to enrich for BCSCs [17].  
Our data demonstrated that H4R agonists enhanced MCF-7 and MDA-MB-231 
mammospheres formation, supporting the participation of TGF-β1 possibly via an 
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autocrine loop. In agreement with our findings, Scheel and colleagues described the 
TGF-β pathway as a relevant signaling pathway involved in the activation of the EMT 
program and functioning in an autocrine fashion to maintain the mesenchymal state in 
the breast [52].  
The relationship between cell adhesion, EMT, and the acquisition of stem cell properties 
has been recently discussed [58]. The loss of E-cadherin by EMT induction in breast 
cancer cells is associated with increased CD44 expression and stemness [18]. In 
agreement with these reports, we could observe an enhancement in the simultaneous 
expression of CD44 and the EMT transcription factor Slug in MCF-7 cells treated with 
H4R agonists. Although we could not verify this association in the TNBC cell line MDA-
MB-231, a meta-analysis recently conducted with breast tumor biopsies revealed that 
the most aggressive breast cancers like the basal-type exhibit elevated levels of CD44 
expression associated with EMT, cancer stem cell gene profiles and poor prognosis 
[23]. In addition, our results show that H4R agonists enhanced the expression of Slug in 
mammosphere cells and also increased the migratory properties of cells derived from 
tumor spheres suggesting a potential link between EMT and the mammosphere-forming 
ability, an attribute of BCSC. In line with this, it was reported a complex connection 
between stemness, cellular plasticity, and EMT mediated by the transcription factor Slug 
in breast cancer [59]. 
In summary, despite the fact that MCF-7 and MDA-MB-231 cells exhibit different 
invasive characteristics our findings indicate that H4R agonists may induce EMT events, 
increase the migratory and invasive properties and enhance mammosphere formation in 
both cell lines. Our results also point out the participation of Src kinase and TGF-β 
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signaling in these events and suggest that intracellular levels of TGF-β1 might maintain 
the mesenchymal state through an autocrine loop.  
The role of the H4 receptor and its ligands in breast tumor progression and metastasis is 
the subject of ongoing studies with controversial results in the last decade. It has been 
reported that the in vitro stimulation of the H4R exerts an inhibitory action on breast 
cancer cell proliferation while the in vivo treatment with the H4R agonist JNJ28 reduces 
tumor growth but increases lung metastases in immune-deficient nude mice 
xenotransplanted with MDA-MB-231 tumor [10,11]. In the light of our results, it might be 
possible that JNJ28 treatment leads to an enrichment of BCSCs in surviving cells of the 
tumor bulk via EMT promotion, which might explain the increased lung metastases 
reported by authors. Meanwhile, Sterle and colleagues studied the immunomodulatory 
function of H4R in breast cancer employing a syngeneic murine model of TNBC and 
reported that mice lacking H4R (H4R knockout) present reduced tumor size and 
decreased number of lung metastases compared to wild type mice [60]. Thus, the role of 
H4R in tumor biology is complex and needs to be further explored.  
In order to improve the survival of cancer patients, researchers must face enormous 
challenges in their fields to find out pharmacological and therapeutic approaches 
targeting specific molecules or steps that govern the primary tumor growth and prevent 
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Effects of H4 histamine receptor ligands on EMT molecular markers in breast 
cancer cells. Epithelial and mesenchymal markers were evaluated by Western blot and 
IFI in MCF-7 (A, B, C) and MDA-MB-231 cells (D, E, F) after 5 days of treatment with 10 
µM VUF8430 (VUF), 10 µM JNJ28610244 (JNJ28) and 10 µM J7777120 (J77). A) 
Immunoblots for E-cadherin, β-catenin, vimentin N-cadherin and alpha-smooth muscle 
actin (α-SMA). A representative Western blot is shown for each protein. β-actin and α-
Tubulin were used as load control and for normalization. Bar chart: mean protein relative 
expression to control ± SEM of three independent experiments. One-way ANOVA. P ns. 
B) Indirect immunofluorescence (IFI) studies were performed to evaluate subcellular 
localization of E-cadherin, β-catenin, vimentin and Slug in MCF-7 cells. Cells were fixed 
and stained with the specific primary antibody and then with Alexa Fluor 488 dye 
conjugated anti-mouse IgG (H+L) or anti rabbit IgG (whole molecule)-FITC antibody as 
appropriate. Nuclei were counterstained with DAPI. Representative photographs are 
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shown. Bar: 20µm. C) Bar chart shows the percentage of Slug positive nuclei in MCF-7 
cells. At least three hundred cells were counted to determine the percentage of Slug 
positive nuclei. Data represent the mean ± SEM of three independent experiments, run 
in duplicate. One-way ANOVA and Bonferroni post-test, *P< 0.05. D) Immunodetection 
of vimentin, N-cadherin and α-SMA in MDA-MB-231 cells. A representative Western blot 
is shown for each protein. Bar chart: mean protein relative expression to control ± SEM 
of three independent experiments. β-actin and α-Tubulin were used as load control and 
for normalization. One-way ANOVA and Bonferroni post-test, *P < 0.05, **P < 0.01, ***P 
< 0.001. E) Subcellular localization of Slug and β-catenin by IFI in MDA-MB-231 cells. 
Cells were fixed and stained with the specific primary antibody and the appropriate 
secondary antibody. Nuclei were counterstained with DAPI. Representative photos are 
shown. Bar: 20 µM. F) Bar chart shows the percentage of Slug positive nuclei in MDA-
MB-231 cells. At least three hundred cells were counted to determine the percentage of 
Slug positive nuclei. Data represent the mean ± SEM of three independent experiments, 
run in duplicate. One-way ANOVA and Bonferroni post-test, *P < 0.05, ***P < 0.001. 
 
Figure 2 
Effects of H4 histamine receptor ligands on cell migration and invasion in MCF-7 
and MDA-MB-231 cells. Co-staining of CD44 and Slug in breast cancer cells. Cell 
migration was evaluated using transwell units after 5 days of treatment with the H4R 
ligand Clobenpropit (CLOB, 10 µM) or VUF8430 (VUF, 10 µM). Breast tumor cells in 
serum-free RPMI medium were seeded in the upper compartment. The lower chamber 
contained RPMI plus 10% FBS. After 40 h (MCF-7) or 20 h (MDA-MB-231) migrated 
cells were fixed and stained. MCF-7: A, B, C. A) Bar chart represents the total number of 
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migrated cells (mean ± SEM) from three independent experiments, run in duplicate. 
One-way ANOVA and Bonferroni post-test, *P < 0.05; **P < 0.01. B) Representative 
photographs of migration studies are shown. Bar: 20 µm.  C) Cell invasion was 
evaluated using transwell units coated with Matrigel®. Bar chart represents the total 
number of invading cells (mean ± SEM) from three independent experiments, run in 
duplicate. One-way ANOVA and Bonferroni post-test, *P < 0.05, **P < 0.01, ***P <0.001 
and ****P < 0.0001. MDA-MB-231: D, E, F. D) Bar chart represents the total number of 
migrated cells (mean ± SEM) from three independent experiments, run in duplicate. 
One-way ANOVA and Bonferroni post-test, ***P < 0.01, ****P < 0.0001. E) 
Representative photographs are shown. Bar: 20 µm.  F) Cell invasion was evaluated 
using transwell units coated with Matrigel®. Bar chart represents the total number of 
invading cells (mean ± SEM) from three independent experiments, run in duplicate. One-
way ANOVA and Bonferroni post-test, * <0.05 and **p < 0.01. G) CD44 and Slug were 
detected simultaneously by indirect immunofluorescence (IFI) in breast tumor cells after 
5 days of treatment with VUF8430 (VUF, 10 µM). Cells were incubated with the primary 
antibodies during 24 h and then with Alexa Fluor 546 dye conjugated anti-mouse IgG 
(H+L) and anti-rabbit IgG (whole molecule)-FITC antibodies during 1 h. Representative 
photos are shown. Bar: 20µm.   
 
Figure 3 
H4 histamine receptor agonists induce EMT events via Src phosphorylation. A) 
Immunodetection of phospho-Src (P-Src) and total Src (T-Src) levels in breast cancer 
cells. MCF-7 and MDA-MB-231 cells were serum-starved during 24 h. Then cells were 
stimulated with 10 µM VUF8430 (VUF) and 10 µM JNJ28610244 (JNJ28) during 15 min. 
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The H4R antagonist JNJ7777120 (J77, 10 µM) and the selective Src inhibitor PP2 (1 
µM) were added 30 min before H4R agonists for combined treatment. A representative 
Western blot is shown for each cell line. β-actin was used as load control and for 
normalization. Bar chart on the right: mean protein relative expression to control ± SEM 
of three independent experiments. One-way ANOVA and Bonferroni post-test, *P < 0.05, 
**P < 0.01, ***P < 0.001. B) P-Src mediates Slug nuclear localization in breast tumor 
cells. MCF-7 and MDA-MB-231 cells were treated with 10 µM JNJ28610244 (JNJ28) 
during 5 days. The selective Src inhibitor PP2 (1 µM) was added 30 min before JNJ28 
for combined treatment. Slug immunodetection was performed by indirect 
immunofluorescence (IFI). Nuclei were counterstained with DAPI. Bar: 20µm. 
Representative photos for each cell line are shown on the left. Bar charts on the right 
show the mean percentage of Slug positive nuclei from three independent IFI 
experiments, run in duplicate. At least three hundred cells were counted to determine 
the percentage of Slug positive nuclei. Data represent the mean ± SEM. One-way 
ANOVA and Bonferroni post-test, **P < 0.01, ***P < 0.001. C) Activation/phosphorylation 
of Src mediates MCF-7 and MDA-MB-231 cell migration. Cell migration was evaluated 
using transwell units after 5 days of treatment with the H4R ligand VUF8430 (VUF, 10 
µM). The selective Src inhibitor PP2 (1 µM) was added 30 min before VUF for combined 
treatment. Breast tumor cells in serum-free RPMI medium were seeded in the upper 
compartment. The lower chamber contained RPMI plus 10% FBS. After 40 h (MCF-7) or 
20 h (MDA-MB-231) migrated cells were fixed and stained. Bar charts represent the total 
number of migrated cells (mean ± SEM) from three independent experiments, run in 





TGF-β signaling is induced by H4 histamine receptor agonists in breast cancer 
cells. A) Detection of Phospho-Smad2/3 (P-Smad) by indirect immunofluorescence (IFI) 
in breast tumor cells. MCF-7 and MDA-MB-231 cells were serum starved during 24 h 
and then stimulated with 10 µM VUF8430 (VUF) and 10 µM JNJ28610244 (JNJ28) 
during 1 h. For combined treatments, the selective TGF-β kinase/activin receptor-like 
kinase inhibitor A83-01 (A83, 10 µM) was added 30 min before VUF or JNJ28. Nuclei 
were counterstained with DAPI. Bar charts on the left show the percentage of p-
Smad2/3 positive nuclei from three independent IFI experiments, run in duplicate. At 
least three hundred cells were counted to determine the percentage of p-Smad positive 
nuclei. Data represent the mean ± SEM. One-way ANOVA and Bonferroni post-test, *P 
< 0.05, **P < 0.01, ***P < 0.001. Representative photos for each cell line are shown on 
the right. Bar: 20µm. B) Immunodetection of ERK1/2 MAPK in breast tumor cells. MCF-7 
and MDA-MB-231 cells were serum starved during 24 h and then stimulated with 10 µM 
VUF8430 (VUF) and 10 µM JNJ28610244 (JNJ28) during 15 min. For combined 
treatments, the selective inhibitor A83 (10 µM) was added 30 min before VUF or JNJ28. 
A representative immunoblotting of phospho-ERK1/2 (P-ERK) and total ERK1/2 (T-
ERK1/2) in each cell line is shown. α-Tubulin was used as load control and for 
normalization. Bar chart: mean protein relative expression to control ± SEM of three 
independent experiments. One-way ANOVA and Bonferroni post-test, *P < 0.05, **P < 





H4 histamine receptor agonists modulate TGF-β1 levels and increase Slug nuclear 
localization and migration in breast cancer cells. A) Intracellular TGF-β1 detection in 
breast tumor cells. MCF-7 and MDA-MB-231 (MDA) cells were treated with 10 µM 
VUF8430 (VUF) and 10 µM JNJ28610244 (JNJ28) during 5 days. The selective TGF-β 
kinase/activin receptor-like kinase inhibitor A83-01 (A83, 10 µM) was added 30 min 
before JNJ28 for combined treatments. A representative Western blot is shown for each 
cell line. α-Tubulin was used as load control and for normalization. Full length 44 kDa 
form was detected. Bar chart: mean protein relative expression to control ± SEM of three 
independent experiments. One-way ANOVA and Bonferroni post-test, *P < 0.05, **P < 
0.01. B) Immunodetection of TGF-β1 in conditioned media from cell cultures. MCF-7 and 
MDA-MB-231 (MDA) cells were treated with 10 µM Clobenpropit (CLOB), 10 µM 
VUF8430 (VUF) and 10 µM JNJ28610244 (JNJ28) during 5 days. A83 (10 µM) was 
added 30 min before JNJ28 for combined treatments. Then, media were replaced by 
serum free-RPMI and after 8 h the conditioned media from cell cultures were collected 
and cleared by centrifugation. Cells from cell cultures were harvested and processed for 
α-Tubulin immunoblotting to be used as load control and for normalization. 25 kDa 
dimeric form was detected. C) Slug cellular localization was evaluated by IFI in breast 
tumor cells. MCF-7 and MDA-MB-231 were treated with 10 µM JNJ28610244 (JNJ28) 
during 5 days. A83 (10 µM) was added 30 min before JNJ28 for combined treatment. 
Nuclei were counterstained with DAPI. Representative photos are shown. Bar: 20µm. 
Bar charts on the right show the percentage of Slug positive nuclei from three 
independent IFI experiments, run in duplicate. At least three hundred cells were counted 
to determine the percentage of Slug positive nuclei. Data represent the mean ± SEM. 
One-way ANOVA and Bonferroni post-test, *P < 0.05, **P < 0.01. D) Cell migration was 
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evaluated after 5 days of treatment with 10 µM VUF8430 (VUF) and 10 µM 
JNJ28610244 (JNJ28). For combined treatments, A83 (10 µM) was added 30 min 
before VUF or JNJ28.  Bar chart represents the total number of MCF-7 or MDA-MB-231 
(MDA) migrated cells (mean ± SEM) from three independent experiments, run in 
duplicate. One-way ANOVA and Bonferroni post-test, *P < 0.05, **P< 0.01. 
 
Figure 6 
H4 Histamine receptor agonists promote mammosphere formation in MCF-7 and 
MDA-MB-231 cells and enhance Slug fluorescence stain and migration of 
mammosphere cells. A) Mammosphere formation was evaluated in MCF-7 and MDA-
MB-231 (MDA) cells after 5 days of treatment with the H4R agonists VUF8430 (VUF, 10 
µM) and JNJ28610244 (JNJ28, 10 µM) combined or not with the H4R antagonist 
J7777120 (J77, 10 µM) or the selective TGF-β kinase/activin receptor-like kinase 
inhibitor A83-01 (A83, 10 µM). Representative photoghaphs are shown. Bar: 50µm. Bar 
charts show the total number of mammospheres/well (mean ± SEM) from three 
independent experiments, run in duplicate. One-way ANOVA and Bonferroni post-test, 
*P < 0.05, **P < 0.01 and ***P< 0.001. B) Indirect immunofluorescence (IFI) studies for 
Slug detection were performed using intact mammospheres. Representative photos of 
the immunodetection of Slug in MCF-7 (Bar: 50µm) and MDA cells (Bar: 20µm) are 
shown. C) MCF-7 and MDA-MB-231 mammospheres were collected by gentle 
centrifugation (1,000 × g) after 7–10 days and were dissociated enzymatically. Cells 
were used for cell migration assay as previously described. Bar charts represent the 
total number of MCF-7 and MDA-MB-231 migrated cells as mean ± SEM from three 





























   MCF-7  MDA-MB-231 
 Control VUF Control      VUF 
Slug   4 ± 2       13 ± 3 23 ± 3          42 ± 2 
CD44 45 ± 4   67 ± 8 93 ± 2          95 ± 2 
Co-staining  3 ± 2    12 ± 2** 20 ± 3         39 ± 2** 
 
Table 1. Immunodetection of Slug and CD44 in breast cancer cells. Co-staining of 
Slug and CD44 was evaluated by indirect immunofluorescence (IFI) in MCF-7 and MDA-
MB-231 cells after five days of treatment with the H4R agonist VUF (10 µM). Cells were 
incubated with the primary antibodies during 24 h and then with Alexa Fluor 546 dye 
conjugated anti-mouse IgG (H+L and anti rabbit IgG (whole molecule)-FITC antibodies 
during 1 h. Nuclei were counterstained with DAPI. At least three hundred cells were 
counted to determine the percentage of CD44 and Slug with or without merge.  Table 
shows the mean percentage of positive cells for CD44 and Slug ± SEM of three 
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